Stock Chart
SLS
Type: SELL wallstreet
Strike: $7
Premium: $2.40
Expiry: Jan 15, 2027
Target: $7
Score: -100
LEAPs are long-term options (1+ year) with less time decay.
Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech
Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity
Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Technical Chart
About SLS - SELLAS Life Sciences Group, Inc. Common Stock
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Key Statistics
More SLS Analysis
This SLS stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track SLS's price movements with trendlines, gamma walls, and key support/resistance levels.